Augmedix (NASDAQ:AUGX) Stock Rating Reaffirmed by Lake Street Capital

Augmedix (NASDAQ:AUGX)‘s stock had its “hold” rating restated by stock analysts at Lake Street Capital in a research note issued to investors on Monday, MarketBeat reports.

A number of other equities research analysts have also issued reports on AUGX. Evercore ISI lowered shares of Augmedix from an “outperform” rating to an “inline” rating and decreased their target price for the company from $5.00 to $1.50 in a research note on Tuesday, May 14th. B. Riley downgraded Augmedix from a “strong-buy” rating to a “hold” rating and dropped their price objective for the stock from $3.00 to $2.35 in a report on Friday, July 19th. Finally, Maxim Group downgraded shares of Augmedix from a “buy” rating to a “hold” rating and set a $5.00 target price for the company. in a research report on Tuesday, May 14th. Four equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.09.

Augmedix Stock Down 0.4 %

NASDAQ:AUGX opened at $2.26 on Monday. Augmedix has a 1-year low of $0.73 and a 1-year high of $6.25. The firm has a market capitalization of $110.67 million, a price-to-earnings ratio of -5.26 and a beta of -0.27. The company has a current ratio of 2.04, a quick ratio of 2.04 and a debt-to-equity ratio of 0.73. The business’s fifty day moving average price is $1.02 and its 200 day moving average price is $2.93.

Augmedix (NASDAQ:AUGX) last issued its earnings results on Monday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The company had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.25 million. Augmedix had a negative return on equity of 178.34% and a negative net margin of 41.95%. On average, sell-side analysts forecast that Augmedix will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AUGX. Norden Group LLC grew its holdings in Augmedix by 50.2% during the first quarter. Norden Group LLC now owns 19,152 shares of the company’s stock valued at $78,000 after purchasing an additional 6,401 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Augmedix in the 1st quarter worth $56,000. SG Americas Securities LLC acquired a new position in Augmedix during the 1st quarter worth $57,000. Symmetry Peak Management LLC bought a new stake in Augmedix during the fourth quarter valued at about $88,000. Finally, Vontobel Holding Ltd. boosted its stake in Augmedix by 9.0% during the 4th quarter. Vontobel Holding Ltd. now owns 188,815 shares of the company’s stock valued at $1,105,000 after purchasing an additional 15,606 shares during the period. 87.11% of the stock is owned by institutional investors.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.